NCT06863272 2026-03-16
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT07258407 2026-03-16
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
Phase 1/2 Recruiting
NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07225946 2026-03-13
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07047118 2026-03-02
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Recruiting
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT04337580 2026-02-20
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT06242470 2026-02-05
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Recruiting
NCT06067841 2026-02-04
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 1 Recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting